A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients Percentage of progression vs survival [...]
Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy Progress free trial CONTACT US Summary Cytokine-induced killer (CIK) cells [...]
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer Change in expression CONTACT US Summary In recurrent ovarian and [...]
Clinical efficacy analysis of dendritic cell-cytokine induced killer cell immunotherapy combined with paclitaxel-cisplatin chemotherapy in patients with advanced ovarian cancer DC-CIK-CHEMOTHERAPY CONTACT US Summary The study aims to investigate [...]
Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-a and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases Overall Survival CONTACT US [...]
Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers Overall Survival CONTACT US Summary This study investigates the correlation of cytokines produced [...]
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02) Overall survival rate CONTACT US Summary The data aims to examine patients with platinum-sensitive ovarian [...]
Phase I/II clinical trial of modulated electro- hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer Stages of ovarian cancer CONTACT US Summary This [...]
Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial Results of the treatment CONTACT US Summary Patients with Ovarian cancer [...]
The future of cancer health, available now.
© Copyright 2022 | All rights reserved. © Immucura
